Sign Out
Letrozole is not indicated in hormone receptor negative diseases.
Adjuvant Treatment of Early Breast Cancer: Letrozole is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.
Extended Adjuvant Treatment of Early Breast Cancer: Letrozole is indicated for the extended adjuvant treatment of invasive early breast cancer in postmenopausal women, who have received 5 years of standard adjuvant tamoxifen therapy.
First and Second-Line Treatment of Advanced Breast Cancer: Letrozole is indicated for first-line treatment of postmenopausal women with hormone dependent advanced breast cancer. Letrozole is also indicated for the treatment of advanced breast cancer after relapse or disease progression in women with natural or artificially induced postmenopausal endocrine status, who have previously be treated with anti-estrogens.
